Khattar Jack A.

Khattar Jack A., President and CEO, has been a consistent seller of Supernus Pharmaceuticals (SUPN) stock over the past year, with no open-market purchases recorded across his 53 total transactions. His selling activity spans two companies—SUPN and Cognition Therapeutics (CGTX)—but the overwhelming majority of dollar volume is concentrated in SUPN, where he has executed multiple sales totaling roughly $20.3 million. The most recent cluster of sales occurred on March 13, 2026, when he disposed of SUPN shares in three separate transactions valued at $6,210, $547,842, and $1.2 million, respectively. Prior to that, he sold SUPN stock on October 9, 2025, for $78,682 and $2.95 million, and on October 1-2, 2025, for $1.93 million and $91,506. These sales were frequently paired with option exercises (coded "M") and tax-withholding dispositions (coded "F"), which are mechanical events rather than discretionary trades. The pattern reveals a clear sell-side bias: every open-market transaction in the data is a sale, with zero purchases (coded "P") or acquisitions (coded "A" as compensation grants) that would indicate fresh capital deployment. The compensation grants—such as the SUPN awards on February 18 and February 28, 2026, and the CGTX award on June 17, 2026—carry no dollar value and represent standard equity compensation, not conviction buying. The sales themselves are substantial, with the largest single disposition reaching $2.95 million on October 9, 2025, and the March 2026 cluster totaling approximately $1.76 million. Notably, the October 7, 2025, transactions in SCPH (scPharmaceuticals) were coded "D" (sale back to issuer) and "U," all with zero value, suggesting corporate actions rather than market sales. The recent direction is unambiguous: seven of the last eight transactions in the data are sales or tax-related dispositions, with the only non-sale being a zero-value grant. The absence of any open-market purchases across the entire filing history—spanning two companies and 53 events—indicates that Khattar has not added to his positions with personal capital during this period. His selling is concentrated in SUPN, where he has monetized option exercises and existing holdings through a series of staggered dispositions, while his involvement with CGTX and SCPH appears limited to compensation and corporate restructuring events rather than active trading.